Results

Total Results: 1,752 records

Showing results for "adverse events".
Users also searched for: patient safety indicators

  1. effectivehealthcare-admin.ahrq.gov/products/breast-biopsy-update/research
    December 01, 2019 - An AHRQ evidence report on the comparative effectiveness and adverse events of breast biopsy methods … The absolute incidence of adverse events was low and the incidence of severe complications was less than … events, or clinical outcomes. … Studies reported adverse events incompletely, and did not provide details of their outcome ascertainment … events.
  2. effectivehealthcare-admin.ahrq.gov/products/glucocorticoid-injections/clinician
    November 01, 2017 - There were more reported adverse events in the glucocorticoids-pluslidocaine group than in the lidocainealone … The most common adverse events were fever/infection and headache in the glucocorticoidsplus-lidocaine … Among participants receiving glucocorticoids plus lidocaine, there were more adverse events with a transforaminal … Serious adverse events (hospitalization or surgery) were rare among all patients. … Injection of glucocorticoids increased the rate of adverse events and the risk of adrenal cortisol suppression
  3. effectivehealthcare-admin.ahrq.gov/products/anxiety-children/research-2017
    January 01, 2020 - based on all three reporters (child, parent, and clinician) and are more likely to cause short-term adverseevents. … Long-term adverse events require further study. … Medications increased short-term adverse events that were mostly not serious (low or moderate SOE). … events, which were mostly not serious, but studies were too small or too short to assess suicidality
  4. effectivehealthcare-admin.ahrq.gov/products/rheumatoid-arthritis-medicine/research
    December 01, 2019 - Similar overall tolerability profiles were found among oral and biologic DMARDs, but short-term adverseevents were more common with biologic DMARDs. … Certolizumab and infliximab had more, while etanercept had fewer withdrawals due to adverse events than … Evidence was insufficient to assess comparative risk of serious adverse events among biologic DMARDs. … Combinations of biologic DMARDs have higher rates of serious adverse events than biologic DMARD monotherapy
  5. Layout 1 (pdf file)

    effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/high-cholestorol-medications_executive.pdf
    September 01, 2009 - Long-Term Benefits and Serious Adverse Events There are several important limitations in the evidence … Absolute rates of serious adverse events varied between 2 and 4 percent. … Early withdrawal due to adverse events was more likely for the combination of statin plus niacin than … However, three of six trials showed significantly more participants experiencing adverse events with … Long-Term Benefits and Serious Adverse Events • The comparator for trials of combination therapy in
  6. effectivehealthcare-admin.ahrq.gov/sites/default/files/nonopioid-chronic-pain-summary.pdf
    April 01, 2020 - • Small to moderate, dose-dependent increases in withdrawal due to adverse events were found with … Harms and adverse events: – What are the risks of nonopioid pharmacologic agents for harms including … overdose, misuse, dependence, withdrawals due to adverse events, and serious adverse events, and … specific adverse events? … Other adverse events of interest were not reported (cognitive effects, misuse, addiction, substance
  7. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
    January 01, 2006 - COX-2s vs NSAIDs - tolerability Trial Withdrawals due to adverse events Total adverse events … COX-2s vs NSAIDs - tolerability Trial Withdrawals due to adverse events Total adverse events … COX-2s vs NSAIDs - tolerability Trial Withdrawals due to adverse events Total adverse eventsAdverse Effects Reported Total withdrawals; withdrawals due to adverse events Tugwell 2004 Not … due to adverse events Appendix F.
  8. effectivehealthcare-admin.ahrq.gov/products/adhd/research
    December 01, 2019 - Structured Abstract Objectives (1) Compare effectiveness and adverse events of interventions (pharmacological … high risk for attention deficit hyperactivity disorder (ADHD); (2) compare long-term effectiveness and adverseevents of interventions for ADHD among persons of all ages; and (3) describe how identification and … Adverse effects were present for preschool children treated with MPH; adverse effects were not mentioned … from administrative databases, provided inconclusive evidence for growth, cerebrovascular, and cardiac adverse
  9. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/diagnostic-error-executive-summary.pdf
    August 01, 2023 - Some of these patients suffer an adverse event because of the incorrect diagnosis (~2.0%), and some … of these adverse events are serious (~0.3%). … events, and 75 serious harms, including 50 deaths per ED. … events with preventable harms; and 371,000 (PR 142,000 to 909,000) serious misdiagnosis-related harms … Serious misdiagnosis-related harms in malpractice claims: The “Big Three” – vascular events, infections
  10. effectivehealthcare-admin.ahrq.gov/products/plant-based-chronic-pain-treatment/living-review
    September 01, 2024 - There may be no increase in risk of serious adverse events (SAEs) (SOE: low) or withdrawal due to adverse … There was no effect on study withdrawals due to adverse events (WAEs). … Intervention Withdrawal due to Adverse Events Serious Adverse Events Dizziness Nausea Sedation Comparable … Other adverse events (e.g. sexual dysfunction) may need to be studied as new data emerge. … In reporting on specific adverse events, not all studies were clear about whether the events were the
  11. effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/binge-eating_clinician.pdf
    May 01, 2016 - systematic review evaluating the evidence regarding the effectiveness, comparative effectiveness, and adverse … Topiramate also increased binge-eating abstinence. �� Adverse effects of BED treatments were mainly … Table 2: Summary of Key Findings for Adverse Effects of Pharmacological Interventions Intervention and … Comparator N RCTs N Subjects N Reported Events (Intervention vs. … events, serious adverse events, and study discontinuations clearly attributable to adverse events,
  12. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/registries-guide-2nd-edition_disposition-comments.pdf
    March 03, 2010 - events, specifically "serious and/or life threatening adverse events." … The pros and cons of using a registry for reporting adverse events are addressed in the "Adverse Event … events.. … events and the association (if any) between exposures and adverse event rates. … In the U.S., adverse events are submitted through the FDA’s MedWatch program.
  13. effectivehealthcare-admin.ahrq.gov/sites/default/files/pdf/headaches-pregnancy.pdf
    March 23, 2019 - events o Maternal  Serious maternal adverse events* • “Serious” adverse events (including those … events* o Fetal/infant  Serious fetal/infant adverse events* • “Serious” adverse events (including … events o Maternal  Serious maternal adverse events* • “Serious” adverse events (including those … events* o Fetal/infant  Serious fetal/infant adverse events* • “Serious” adverse events (including … ) due to neonatal/infant adverse events.
  14. effectivehealthcare-admin.ahrq.gov/products/headaches-pregnancy/protocol
    May 01, 2020 - Adverse events: Maternal: Serious maternal adverse events:* "Serious" adverse events ( … /infant: Serious fetal/infant adverse events:* "Serious" adverse events (including those that … Adverse events: Maternal: Serious maternal adverse events:* "Serious" adverse events ( … /infant: Serious fetal/infant adverse events:* "Serious" adverse events (including those that … ) due to neonatal/infant adverse events.
  15. effectivehealthcare-admin.ahrq.gov/sites/default/files/product/pdf/research-gap-primary-care-summary-table.pdf
    March 01, 2022 - Evidence is insufficient to draw conclusions about serious adverse events. … Evidence is insufficient to draw conclusions about serious adverse events. … events, nausea, dizziness, and somnolence, but serious adverse events are uncommon in randomized … Large increases in withdrawal due to adverse events were seen with oxcarbazepine. … characterization of what adverse events to expect.
  16. effectivehealthcare-admin.ahrq.gov/sites/default/files/back-pain-treatment_research_executive.pdf
    February 01, 2016 - placebo: Adverse events Low A systematic review found that central nervous system adverse events such … placebo: Adverse events, serious adverse events Moderate Antidepressants were associated with higher … in risk of adverse events. … Yoga: Adverse events Low Reporting of harms was suboptimal, but adverse events, when reported, were … No serious adverse events were reported, and most adverse events were related to muscle soreness or
  17. effectivehealthcare-admin.ahrq.gov/products/prioritization-patient-safety-practices
    January 01, 2024 - Supported by Clinical Pharmacists The Clinical Pharmacist's Role in Preventing Adverse Drug Events Adverse … Drug Events: Harms due to Anticoagulants Single Provider Adverse Drug Events: Infusion Pumps/Medication … Error Staff Education and Training Structured Process Changes/Workflow Redesign Adverse Drug Events: … Reducing Adverse Drug Events in Older Adults Use of Screening Tool of Older People's Prescriptions ( … Adverse Events in Hospitals: A Quarter of Medicare Patients Experienced Harm in October 2018. U.S.
  18. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/Appendix-E-Table-E5_0.xlsx
    November 04, 2021 - Events Other Reported Outcomes Funding Source Risk of Bias 21087411 Bestard, 2011 Prospective cohort … C % (n/N) Any adverse event 3 months: 35% (19/49) vs. 47% (30/52) vs. … NR Serious adverse events: none in any group Withdrawals due to adverse events 6 months: 10% (5/49) vs … adverse events: 13% (28/215) vs. 19.4% (42/216), OR 0.64 (95% CI 0.38 to 1.04) Withdrawals due to adverseevents: 4.65% (10/215) vs.
  19. effectivehealthcare-admin.ahrq.gov/sites/default/files/related_files/cannabis-app-f5-table-surveillance-report-2_0_0.xlsx
    February 16, 2022 - Events Other Reported Outcomes Funding Source Risk of Bias 21087411 Bestard, 2011 Prospective cohort … C % (n/N) Any adverse event 3 months: 35% (19/49) vs. 47% (30/52) vs. … NR Serious adverse events: none in any group Withdrawals due to adverse events 6 months: 10% (5/49) vs … adverse events: 13% (28/215) vs. 19.4% (42/216), OR 0.64 (95% CI 0.38 to 1.04) Withdrawals due to adverseevents: 4.65% (10/215) vs.
  20. effectivehealthcare-admin.ahrq.gov/products/antiplatelet-treatment/research
    December 01, 2019 - events from testing itself or from test-directed treatment. … cardiovascular events (RR=1.20; 95% CI, 1.04 to 1.39); and cardiovascular mortality (RR=1.98; 95% CI … of loss-of-function alleles and all-cause mortality, acute coronary syndromes, stroke, and bleeding events … cardiovascular events and stent thrombosis) produced results in the same direction but with larger effect … cardiovascular events (RR=0.82; 95% CI, 0.74 to 0.92).

Search the AHRQ Archive

Information and reports more than 5 years old may be found in the AHRQ Archive site.

Search Archive

Search Within A Specific AHRQ Site

You selected to view results for the following site: